Revolution Medicines Shares Rise About 6% After Q3 Results Beat

The company reaffirmed its 2026 GAAP operating expense range of $2.1 billion to $2.2 billion and posted a $1.90 per-share loss.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.